ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products. By combining complementary expertise, the collaboration aims to address one of the longstanding challenges in biologic formulation development: the limited availability of excipients suitable for injectable medicines.

A new peer-reviewed study in JCI Insight by DTU and Cytosurge reveals dermokine’s critical role in wound healing and skin cancer. To decode these mechanisms, researchers used Cytosurge’s CellEDIT service to successfully engineer notoriously fragile human keratinocytes. By bypassing the toxicity of traditional bulk transfection, CellEDIT’s vector-free, direct-to-nucleus CRISPR delivery genera

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA action date set for April 23, 2027

Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027

In a collaboration with a leading global pharmaceutical company, Volv Global applied machine learning to 24 million UK primary care records, surfacing approximately 1,200 likely-undiagnosed GEP-NET patients – and finding they are 5–7 years younger than those currently diagnosed. Approximately 1,200 UK patients have records consistent with undiagnosed GEP-NETs – roughly one additional patient